Information page of

A new study in
idiopathic pulmonary fibrosis

A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With Idiopathic Pulmonary Fibrosis.

The main purpose of this study is to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated (for example if you get any side effects while on study drug). For more information visit:

This site will be updated in the near future.


Q&A about the study:

Sign up for future updates

If you have interest in future updates from the Isabela studies team, please sign up: